NCT07516444ClinicalTrials.gov
VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)
VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation
Kurz gefasst
Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.
Interventionell520 Teilnehmende gesucht12 Studienzentren1 Land
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07516444Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert letzte Woche
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-04-08; recorded start 2026-07-28
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (VDyne, Inc.)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 8 conditions.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding7/20
Single-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 520 participants (target), run at 12 sites.
How this score is built
- Enrolment28/40
730 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration10/10
Planned over about 122 months
- Sponsor scale1/10
VDyne, Inc. has led 3 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.
Erkrankungen
- Tricuspid Valve Regurgitation
- Tricuspid Valve Disease
- Cardiovascular Diseases (CVD)
- Heart Valve Diseases
- Tricuspid Valve Insufficiency
- Severe Heart Valve Disease
- Randomized Controlled Trial (RCT)
- Symptomatic Tricuspid Regurgitation
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Nicht zutreffend |
| Zuteilung | Randomisiert |
| Interventionsmodell | PARALLEL |
| Primäres Ziel | TREATMENT |
| Verblindung | SINGLE (1) |
| Teilnahme | 520 Teilnehmende gesucht |
Sponsor und Mitwirkende
- VDyne, Inc. Sponsor
Studienarme und Interventionen
- Randomized cohort VDyne TriNova TTVREXPERIMENTAL
Transcatheter tricuspid valve replacement with VDyne TriNova System in patients with severe or greater tricuspid regurgitation.
- Randomized cohort Edwards EVOQUE TTVRACTIVE_COMPARATOR
Transcatheter tricuspid valve replacement with Edwards EVOQUE System in patients with severe or greater tricuspid regurgitation.
- Single Arm RegistryEXPERIMENTAL
Transcatheter tricuspid valve replacement with VDyne TriNova System in patients with severe or greater tricuspid regurgitation who are deemed ineligible to be treated with Active Comparator EVOQUE device.
Interventionen
- Medizinprodukt Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System
Subjects will undergo TTVR procedure with Edwards EVOQUE device and will continue to be managed on Optimal Medical Therapy (OMT).
- Medizinprodukt Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System
Subjects will undergo TTVR procedure with VDyne TriNova device and will continue to be managed on Optimal Medical Therapy (OMT).
Endpunkte
Primärer Endpunkt
Composite of major adverse events (MAEs)
* Cardiovascular mortality * Myocardial infarction * All stroke * New need for renal replacement therapy * Severe bleeding * Non-elective tricuspid valve re-intervention * Major access site and vascular complications * Major cardiac structural complications * Device-related pulmonary embolism * New arrhythmia or conduction disorder requiring permanent pacing
Zeitrahmen 30 days post-procedure
Primärer Endpunkt
Composite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reintervention
Zeitrahmen 12 months post-procedure
Primärer Endpunkt
Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) \* 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.
Zeitrahmen 12 months post-procedure
Primärer Endpunkt
Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)
New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
Zeitrahmen 12 months post-procedure
Sekundärer Endpunkt
All-Cause Mortality
Total number of deaths from any cause
Zeitrahmen At 12 months and 24 months
Sekundärer Endpunkt
RVAD implantation or heart transplant
Total number of patients requiring Right Ventricular Assist Device (RVAD) implantation or heart transplant
Zeitrahmen At 12 months and 24 months
Sekundärer Endpunkt
Tricuspid valve surgical or percutaneous intervention
Total number of non-elective tricuspid valve re-interventions
Zeitrahmen At 12 months and 24 months
Sekundärer Endpunkt
Heart failure hospitalizations
Total number of patients with at least one hospital admission due to heart failure
Zeitrahmen At 12 months and 24 months
Sekundärer Endpunkt
Change in 6-Minute Walk Distance (6MWD)
Functional status improvement, as measured by 6-Minute Walk Test total distance walked. The 6-Minute Walk Test (6MWT) is a test that measures the total distance an individual can walk on a flat, hard surface in 6 minutes. It is commonly used to evaluate functional exercise capacity in patients with conditions including heart failure. The minimum score possible is 0, which would represent an inability to walk any distance. There is no maximum score, as a patient could theoretically walk any distance in 6 minutes though 800 meters considered the top reference range, which is what would be expected by elite athletes. Higher score indicate greater higher exercise capacity and lower scores indicate lower exercise capacity.
Zeitrahmen At 12 months and 24 months
Sekundärer Endpunkt
Change in Echocardiographic Tricuspid Regurgitation (TR) grade from baseline using TransThoracic Echocardiogram (TTE)
Change in Tricuspid Regurgitation (TR) grade from baseline is measured. A 5-tier grading scheme will be used: mild, moderate, severe, massive and torrential. The change in TR grade is assessed using TransThoracic Echocardiogram (TTE) imaging.
Zeitrahmen At 6 months, 12 months and 24 months post-implant compared to baseline
Sekundärer Endpunkt
Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)
New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
Zeitrahmen 12 months post-procedure
Sekundärer Endpunkt
Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) \* 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.
Zeitrahmen 12 months post-procedure
Daten
| Startdatum | 28. Juli 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 1. Juni 2029 (geschätzt) |
| Abschluss | 1. Juni 2036 (geschätzt) |
| Erstveröffentlichung | 8. April 2026 (tatsächlich) |
| Zuletzt aktualisiert | 10. November 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | November 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
12 Studienzentren rekrutieren
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Medical University of South Carolina | Charleston | South Carolina | Rekrutiert |
| The Christ Hospital | Cincinnati | Ohio | Rekrutiert |
| Henry Ford Hospital | Detriot | Michigan | Rekrutiert |
| Minneapolis Heart Institute | Minneapolis | Minnesota | Rekrutiert |
| Intermountain Medical Center | Murray | Utah | Rekrutiert |
| Banner Health | Phoenix | Arizona | Rekrutiert |
| Oregon Health and Science Unversity | Portland | Oregon | Rekrutiert |
| Mayo Clinic | Rochester | Minnesota | Rekrutiert |
| Sutter Health/ California Pacific Medical Center | San Francisco | California | Rekrutiert |
| Kaiser Permanente San Francisco | San Francisco | California | Rekrutiert |
| Honor Health | Scottsdale | Arizona | Rekrutiert |
| Ascension Via Christi Hospital | Wichita | Kansas | Rekrutiert |
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 10. November 2026
Teilnahmeziel geändert
Enrollment target revised down from 730 to 520
730520
- 10. November 2026
Studienzentrum hinzugefügt
11 sites added (12 total)
112
- 17. August 2026
Status geändert
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 17. August 2026
Rekrutierung eröffnet
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 17. August 2026
Studienzentrum hinzugefügt
1 site added (1 total)
01